Ouimette Mike

SEC source: 0001746473-25-000017 · wk-form4_1738019393.xml · derivative · entry 2

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2035-01-23

F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001746473-25-000017 · wk-form4_1738019393.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,544

F1 · shares: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001746473-25-000001 · wk-form4_1737586520.xml · nonDerivative · entry 2

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,544

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $10.88 to $11.21, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.

SEC source: 0001746473-25-000001 · wk-form4_1737586520.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,774

F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001746473-24-000121 · wk-form4_1720822518.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,044

F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001746473-24-000111 · wk-form4_1720730506.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,700

F1 · shares: On July 28, 2022, the Reporting Person was granted 54,374 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 14,954 shares.

SEC source: 0001746473-24-000015 · wk-form4_1706133440.xml · derivative · entry 2

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,000

Underlying: Common Stock · 63,000 shares

Expires 2034-01-23

F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001746473-24-000015 · wk-form4_1706133440.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,746

F1 · shares: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001746473-24-000001 · wk-form4_1705702265.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,246

F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $16.33 to $17.90, inclusive, between January 17, 2024 and January 18, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001209191-23-043085 · doc4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,443

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.67, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0001209191-23-042834 · doc4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,198

F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $17.63 to $18.47, inclusive, between July 17, 2023 and July 19, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001209191-23-042662 · doc4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,976

F1 · shares: On July 28, 2022, the Reporting Person was granted 54,374 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On July 14, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 27,187 shares.

SEC source: 0001209191-23-022376 · doc4.xml · nonDerivative · entry 3

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,789

F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.27 to $27.64, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.

SEC source: 0001209191-23-022376 · doc4.xml · nonDerivative · entry 2

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,989

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.24 to $27.17, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.

SEC source: 0001209191-23-022376 · doc4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,666

F1 · price: Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001209191-23-021927 · doc4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,540

F1 · shares: On July 28, 2022, the Reporting Person was granted 54,375 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 13,593 shares.

SEC source: 0001140361-23-003179 · form4.xml · derivative · entry 2

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2033-01-24

F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-003179 · form4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,947

F1 · shares: These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-002785 · form4.xml · derivative · entry 5

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,240

Underlying: Common Stock · 10,000 shares

Expires 2030-10-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to such option vested on October 1, 2021 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-002785 · form4.xml · derivative · entry 4

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,000

Underlying: Common Stock · 10,000 shares

Expires 2032-01-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-002785 · form4.xml · nonDerivative · entry 3

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,947

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.

SEC source: 0001140361-23-002785 · form4.xml · nonDerivative · entry 2

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,947

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-23-002785 · form4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,947

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-22-046917 · form4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,947

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.86 to $19.57, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001140361-22-046568 · form4.xml · nonDerivative · entry 2

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,875

F2 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0001140361-22-046568 · form4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,594

F1 · shares: On July 28, 2022, the Reporting Person was granted 54,375 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 13,594 shares.

SEC source: 0001567619-22-002401 · doc1.xml · derivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,000

Underlying: Common Stock · 87,000 shares

Expires 2032-01-25

F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0000899243-21-003379 · doc4.xml · derivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,520

Underlying: Common Stock · 15,520 shares

Expires 2031-01-22

F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0000899243-20-028074 · doc4.xml · derivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,240

Underlying: Common Stock · 108,240 shares

Expires 2030-10-08

F1 · derivative.exercise_date: 25% of the shares subject to such option vest on October 1, 2021 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.